WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

/PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Related Keywords

Shanghai ,China ,United States ,Wuxi ,Jiangsu ,Hong Kong ,Changzhou ,Singapore ,Middletown ,Delaware ,Lingang ,Jiangxi ,Wuhan ,Hubei ,America ,Asia Pacific ,International Financial Reporting Standards ,Stock Exchange Of Hong Kong ,Owners Of The Company ,Shanghai Stock Exchange ,Third Quarterly Report Of The Company ,Manufacturing Organization ,Contract Research ,National Medical Products Administration ,Site Management Organization ,Accounting Standard For Business Enterprises ,Profit Attributable ,Earnings Per Share ,Quarterly Report ,Stock Exchange ,Contract Testing ,Reporting Period ,Wuxi Chemistry ,Changzhou Phase ,Wuxi Testing ,Wuxi Apptec Investigational New Drug ,From January ,Wuxi Biology ,Shanghai Lingang ,Tetracycline Enabled Self Silencing Adenovirus ,Licensing Agreement ,Trial Applications ,Proposed Issuance ,Wuxi Apptec ,Financial Position ,North America ,Accounting Standard ,Business Enterprises ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Banking Amp Financial Services ,Earnings ,